NEW YORK (GenomeWeb News) – Diabetes biotechnology firm Islet Sciences today announced it has licensed technology from Winthrop University Hospital for identifying Beta cell death.

The PCR-based technology was developed by Eitan Akirav, a research scientist at WUH, and colleagues to identify Beta cell death before the onset of hyperglycemia and soon after the onset of type 1 diabetes. John Steel, chairman and CEO of Islet, said that his firm will commercialize the technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.